Work

Lessons from the FNIH-NIA-FDA sarcopenia consensus summit

Year: 2012

Type: article

Abstract: This 4-day consensus definition conference was co-organized by the Foundation of National Institutes of Health (FNIH), National Institutes of Aging (NIA) and the Federal Drug Adminstration (FDA), and was co-sponsored by five pharmaceutical companies (Abbott, Amgen, Eli Lilly, Merck and Novartis). Importantly, a consensus definition of sarcopenia, is gradually being enabled through the FNIH Biomarkers Consortium Sarcopenia Project, led by Dr Stephanie Studenski, that has been acting as a neutral convener for academia, industry, FDA, NIH and related professional societies. The Sarcopenia Project came to the 2012 Sarcopenia Consensus Summit prepared with data from thousands of individuals on several major aging longitudinal studies conducted in the United States in the past several decades in hopes of facilitating the definition of sarcopenia.

Source: IBMS BoneKEy

DOI: 10.1038/bonekey.2012.210

Author: Marco Brotto

Institution: University of Missouri–Kansas City

Language: English

Topic: Nutrition and Health in Aging

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Foundation for the National Institutes of Health, Life Sciences Research Board, National Institute on Aging, National Institute of Arthritis and Musculoskeletal and Skin Diseases